Calcimimetics in the treatment of primary hyperparathyroidism

Journal of Bone and Mineral Research

Volumn 17, Issue SUPPL. 2, 2002, Pages

  Antoniucci, Diana M ^a   Shoback, Dolores ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; CALCIUM; CALCIUM SENSING RECEPTOR; CELL SURFACE RECEPTOR; N (2 CHLOROPHENYLPROPYL) 1 (3 METHOXYPHENYL)ETHYLAMINE; N-(2-CHLOROPHENYLPROPYL)-1-(3-METHOXYPHENYL)ETHYLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTICENTER STUDY; NONHUMAN; PRIMARY HYPERPARATHYROIDISM; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; ANIMAL; DRUG POTENTIATION; HYPERPARATHYROIDISM; METABOLISM; MOLECULAR MIMICRY; REVIEW;

ANILINE COMPOUNDS; ANIMALS; CALCIUM; CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM; MOLECULAR MIMICRY; RECEPTORS, CALCIUM-SENSING; RECEPTORS, CELL SURFACE;

EID: 0036840492     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Strewler GJ 2000 Medical approaches to primary hyperparathyroidism. Endocrinol Metabol Clin North Am 29:523-539.
2. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255.
3. 2+ -sensing receptor from bovine parathyroid. Nature 366:575-580.
4. Nemeth EF, Steffey ME, Hammerland LG, Hung BCP, Van Wagenen BC, Del Mar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045.
5. Nemeth EF 1999 Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66-71.
6. Brown EM, MacLeod RJ 2001 Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239-297.
7. Fox J, Lowe SH, Petty BA, Nemeth EF 1999 NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290:473-479.
8. 2+ receptor in rats. J Pharmacol Exp Ther 290:480-486.
9. Lalonde RL, Gaudreault J, Karhu DA, Marriott TB 1999 Mixed-effects modeling of the phamacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther 65:40-49.
10. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53:1083-1088.
11. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N 1998 NPS R-568 halt or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453.
12. Wada M, Furuya Y, Sakiyama J-I, Kobayashi N, Miyata S, Ishii H, Nagano N 1997 The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via calcium receptor. J Clin Invest 100:2977-2983.
13. Silverberg SJ, Bone HG III, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP 1997 Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506-1510.
14. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088.
15. Antonsen JE, Sherrard DJ, Andress DL 1998 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227.
16. Shoback DM, Bilezikian J, Binder TA, Graves T, Turner SA, Peacock M 2000 Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism. J Bone Miner Res 15:S1;S210.
17. Shoback DM, Firek AF, Mims RB, Binder TA, Graves T, Turner SA, Peacock M 2001 An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism. J Bone Miner Res 16:S1;S303.
18. Peacock M, Shoback DM, Greth WE, Binder TA, Graves T, Brenner RM, Turner SA, Marcus R 2001 The calcimimetic AMG 073 reduces serum calcium in patients with primary hyperparathyroidism. J Bone Miner Res 16:S1;S163.
19. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW 2002 The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024.
20. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, Del Mar EG, Miller MA, Nemeth EF, Fox J 2000 Antagonizing the parathyroid calcium receptor stimulate parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595-1604.
21. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharm Exp Ther 299:323-331.